​

Bolt Biotherapeutics (BOLT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

BOLT Stock Forecast

Bolt Biotherapeutics (BOLT) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $7.00, with a high of $7.00 and a low of $7.00. This represents a 16.67% increase from the last price of $6.00.

- $1 $2 $3 $4 $5 $6 $7 High: $7 Avg: $7 Low: $7 Last Closed Price: $6

BOLT Stock Rating

Bolt Biotherapeutics stock's rating consensus is Hold, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 2 Buy (25.00%), 6 Hold (75.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 8 0 6 2 Strong Sell Sell Hold Buy Strong Buy

BOLT Price Target Upside V Benchmarks

TypeNameUpside
StockBolt Biotherapeutics16.67%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts111
Avg Price Target$7.00$7.00$7.00
Last Closing Price$6.00$6.00$6.00
Upside/Downside16.67%16.67%16.67%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25-13--4
Sep, 25-13--4
Aug, 25-13--4
Jul, 25-13--4
Jun, 25-13--4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 20, 2025H.C. Wainwright$7.00$5.7521.74%16.67%
May 15, 2024Daina GrayboschLeerink Partners$1.00$1.32-24.24%-83.33%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 20, 2025Lake StreetBuyinitialise
May 15, 2024H.C. WainwrightNeutraldowngrade
May 15, 2024Leerink PartnersMarket Performdowngrade
May 14, 2024GuggenheimNeutraldowngrade
May 12, 2023Credit SuisseOutperformupgrade
May 12, 2023MoffettNathansonOutperformupgrade
Aug 11, 2022SVB LeerinkMarket Performdowngrade

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.99$-2.79$-2.30$-1.83$-1.65----
Avg Forecast$-3.80$-3.13$-2.36$-1.74$-1.55$-1.07$-0.79$-0.47$-0.23
High Forecast$-2.32$-1.90$-1.46$-1.58$-1.51$-0.90$-0.49$-0.20-
Low Forecast$-5.56$-4.57$-3.41$-1.83$-1.58$-1.38$-1.48$-0.94$-0.50
Surprise %-47.63%-10.86%-2.54%5.17%6.45%----

Revenue Forecast

$0 $10M $20M $30M $40M $50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$231.00K$1.26M$5.73M$7.88M$7.69M----
Avg Forecast$265.50K$1.96M$5.68M$7.59M$8.47M$4.53M$7.16M$17.55M$25.00M
High Forecast$359.75K$2.66M$7.62M$8.08M$8.62M$8.84M$13.95M$34.21M$48.73M
Low Forecast$185.65K$1.37M$4.01M$7.14M$8.19M$998.53K$1.58M$3.87M$5.51M
Surprise %-12.99%-35.74%0.89%3.77%-9.17%----

Net Income Forecast

$-250M $-190M $-130M $-70M $-10M $50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-72.27M$-104.39M$-85.88M$-69.20M$-63.12M----
Avg Forecast$-143.81M$-118.28M$-89.17M$-69.20M$-58.30M$-43.12M$-37.24M$-21.56M$-8.51M
High Forecast$-87.58M$-72.03M$-55.14M$-59.89M$-57.03M$-34.06M$-18.50M$-7.51M$116.18K
Low Forecast$-210.18M$-172.86M$-128.87M$-69.31M$-59.57M$-52.18M$-55.99M$-35.60M$-19.01M
Surprise %-49.74%-11.74%-3.70%-8.26%----

BOLT Forecast FAQ

Is Bolt Biotherapeutics stock a buy?

Bolt Biotherapeutics stock has a consensus rating of Hold, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 2 Buy, 6 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Bolt Biotherapeutics is a neutral investment for most analysts.

What is Bolt Biotherapeutics's price target?

Bolt Biotherapeutics's price target, set by 8 Wall Street analysts, averages $7 over the next 12 months. The price target range spans from $7 at the low end to $7 at the high end, suggesting a potential 16.67% change from the previous closing price of $6.

How does Bolt Biotherapeutics stock forecast compare to its benchmarks?

Bolt Biotherapeutics's stock forecast shows a 16.67% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Bolt Biotherapeutics over the past three months?

  • October 2025: 0% Strong Buy, 25.00% Buy, 75.00% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 0% Strong Buy, 25.00% Buy, 75.00% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 0% Strong Buy, 25.00% Buy, 75.00% Hold, 0% Sell, 0% Strong Sell.

What is Bolt Biotherapeutics’s EPS forecast?

Bolt Biotherapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.07, marking a -35.15% decrease from the reported $-1.65 in 2024. Estimates for the following years are $-0.79 in 2026, $-0.47 in 2027, and $-0.23 in 2028.

What is Bolt Biotherapeutics’s revenue forecast?

Bolt Biotherapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $4.53M, reflecting a -41.05% decrease from the reported $7.69M in 2024. The forecast for 2026 is $7.16M, followed by $17.55M for 2027, and $25M for 2028.

What is Bolt Biotherapeutics’s net income forecast?

Bolt Biotherapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-43.121M, representing a -31.68% decrease from the reported $-63.118M in 2024. Projections indicate $-37.244M in 2026, $-21.556M in 2027, and $-8.508M in 2028.